Protocol Ledger

NCT05338086 · Phase III · COMPLETED

A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.

Interventional Phase III clinical trial protocol NCT05338086 sponsored by mAbxience Research S.L in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-16 Enrollment: 558 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05338086
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)558 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05338086
Protocol FieldVerified Registry Value
NCT IdentifierNCT05338086
Consolidated Lead SponsormAbxience Research S.L
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment558 participants (ACTUAL)
Registered Start Date2022-03-16
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI